<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TICARCILLIN DISODIUM/CLAVULANATE POTASSIUM</span><br/>(tye-kar-sill'in/clav-yoo'la-nate)<br/><span class="topboxtradename">Timentin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antipseudomonal penicillin</span><br/><b>Prototype: </b>Piperacillin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3.1 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Injectable extended-spectrum penicillin and fixed combination of ticarcillin disodium with the potassium salt of clavulanic
         acid, a beta-lactamase inhibitor produced by fermentation of <i>Streptomyces clavuligerus</i>. Used alone, clavulanic acid antibacterial activity is weak but in combination with ticarcillin prevents degradation by beta-lactamase
         and extends ticarcillin spectrum of activity against many strains of beta-lactamase-producing bacteria (synergistic effect).
         Synergism between the two drugs does not occur against organisms susceptible to ticarcillin alone.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Susceptible strains of organisms include beta-lactamase strains of <i>Klebsiella</i> sp., <i>Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, Citrobacter</i> sp., <i>Enterobacter cloacae, Serratia marcescens</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Infections of lower respiratory tract and urinary tract and skin and skin structures, infections of bone and joint, and septicemia
         caused by susceptible organisms. Also mixed infections and as presumptive therapy before identification of causative organism.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to penicillins or to cephalosporins. Safety during pregnancy (category B) is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span>
<i>&gt;60 kg,</i> 3.1 g q46h<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>&gt;3 mo,</i> 200300 mg/kg/d divided q46h (based on ticarcillin)<br/><span class="rdage">Infant:</span> <span class="rdroute">IV</span>
<i>, 200300 mg/kg/d divided q68h (based on ticarcillin)<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion for administration to infants and children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute by adding to 3.1 g of powder 13 mL sterile water for injection or NS injection to yield 200 mg/mL ticarcillin
                  with 6.7 mg/mL clavulanic acid. Shake until dissolved. Further dilute with NS, D5W, or RL. Do not use if discoloration or
                  particulate matter is present.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>  Give over 30 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>doxapram.</b>
<span class="incompattype">Y-site:</span>
<span class="classification">aminoglycosides</span>, <b>amphotericin B cholesteryl complex,</b>
<b>azithromycin, vancomycin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store vial with sterile powder at 21°24° C (69°75° F) or colder. If exposed to higher temperature,
            powder will darken, indicating degradation of clavulanate potassium and loss of potency. Discard vial. See package insert
            for information about storage and stability of reconstituted and diluted IV solutions of drug.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity reactions, pain, burning, swelling at injection site; phlebitis, thrombophlebitis; superinfections. <span class="typehead">CNS:</span> Headache, blurred vision, mental deterioration, convulsions, hallucinations, seizures, giddiness, neuromuscular hyperirritability. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea,</span> vomiting, disturbances of taste or smell, stomatitis, flatulence. <span class="typehead">Hematologic:</span> Eosinophilia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia. <span class="typehead">Metabolic:</span> Hypernatremia, transient increases in serum AST, ALT, BUN, and alkaline phosphatase; increases in serum LDH, bilirubin, and
      creatinine and decreased serum uric acid. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May interfere with test methods used to determine <span class="alt">urinary proteins</span> except for tests for urinary protein that use <span class="alt">bromphenol blue. Positive direct antiglobulin (Coombs') test</span> results, apparently caused by clavulanic acid, have been reported. This test may interfere with <span class="alt">transfusion cross-matching procedures.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drugs:</span> May increase risk of bleeding with <span class="classification">anticoagulants</span>; <b>probenecid</b> decreases elimination of ticarcillin. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Widely distributed with highest concentrations in urine and bile; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Slightly metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.11.2 h ticarcillin, 1.11.5 h clavulanate. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline C&amp;S tests before initiating therapy; drug may be started pending results. Monitor kidney and liver
            functions, CBC, platelet count, and serum electrolytes during prolonged treatment.
         </li>
<li>Be aware that serious and sometimes fatal anaphylactoid reactions have been reported in patients with penicillin hypersensitivity
            or history of sensitivity to multiple allergens. Reported incidence is low with this combination drug.
         </li>
<li>Monitor cardiac status because of high sodium content of drug.</li>
<li>Overdose symptoms: This drug may cause neuromuscular hyperirritability or seizures.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report urticaria, rashes, or pruritus to physician immediately.</li>
<li>Report frequent loose stools, diarrhea, or other possible signs of pseudomembranous colitis (see Appendix F) to physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>